Silverfin false false 30/09/2025 30/09/2025 01/10/2024 no description of principal activity Dr S Cudlip 03/09/2020 Professor M Hu 03/09/2020 12855469 2025-09-30 12855469 bus:Director1 2025-09-30 12855469 bus:Director2 2025-09-30 12855469 2024-09-30 12855469 core:CurrentFinancialInstruments 2025-09-30 12855469 core:CurrentFinancialInstruments 2024-09-30 12855469 2024-10-01 2025-09-30 12855469 bus:Micro-entities 2024-10-01 2025-09-30 12855469 bus:FilletedAccounts 2024-10-01 2025-09-30 12855469 bus:AuditExemptWithAccountantsReport 2024-10-01 2025-09-30 12855469 bus:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 12855469 bus:Director1 2024-10-01 2025-09-30 12855469 bus:Director2 2024-10-01 2025-09-30 12855469 2023-10-01 2024-09-30 iso4217:GBP xbrli:pure

Company No: 12855469 (England and Wales)

# OXFORD NEUROSCIENCES LIMITED

### UNAUDITED FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025
PAGES FOR FILING WITH THE REGISTRAR

OXFORD NEUROSCIENCES LIMITED

## UNAUDITED FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025

Contents

OXFORD NEUROSCIENCES LIMITED

## BALANCE SHEET

AS AT 30 SEPTEMBER 2025
OXFORD NEUROSCIENCES LIMITED

## BALANCE SHEET (continued)

FOR THE FINANCIAL YEAR ENDED 30 SEPTEMBER 2025

|  | 2025 |  | 2024
|  | £ |  | £
Fixed assets |  | 6,437 |  | 8,512
Current assets |  | 277,726 |  | 186,836
Prepayments and accrued income |  | 11,529 |  | 11,678
Creditors: amounts falling due within one year |  | ( 28,282) |  | ( 23,068)
Net current assets |  | 260,973 |  | 175,446
Total assets less current liabilities |  | 267,410 |  | 183,958
Accruals and deferred income |  | ( 3,005) |  | ( 2,700)
Net assets |  | 264,405 |  | 181,258
Capital and reserves |  | 264,405 |  | 181,258

#### 1. Company information

The Company is a private company limited by shares and is incorporated in the United Kingdom and registered in England and Wales (Company no. 12855469). The address of its registered office is 4 Harberton Mead, Headington, Oxford, OX3 0DB, United Kingdom.

#### 2. Employees

| 2025 |  | 2024
| Number |  | Number
Monthly average number of persons employed by the Company during the financial year, including directors | 2 |  | 2

#### 3. Directors’ benefits: advances, credit and guarantees

##### Advances

Included in other debtors is £2,796 owed by a director (2024: £253 in other creditors owed to directors.) This amount is unsecured, and is repayable on demand.. No interest has been charged on the amount.

For the financial year ending 30 September 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements;
- These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and FRS 105 The Financial Reporting Standard applicable to the Micro-entities Regime;
- These financial statements have been delivered in accordance with the small companies regime and a copy of the Profit and Loss Account has not been delivered.

The financial statements of Oxford Neurosciences Limited (registered number: 12855469) were approved and authorised for issue by the Board of Directors on 06 March 2026 and were signed on its behalf by:

Dr S Cudlip Director |